Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0697

-0.4%

Nov 24 3:55 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: NTTG	2/21/2012 8:16:39 AM
	2 Recommendations Read Replies (1) of 13111

Roche's B-Raf inhibitor for MM was approved in Europe as mono therapy for unresectable or metastatic patients with the V600 BRAF mutation (Roche also holds the Cobas test for the mutation). The only therapy currently available that extended survival in pivotal clinical trials for these patients. Currently approved in the US,Switzerland, Brazil, Israel, Canada and the EU, in discussion with Australia for market authorization. Even with aging populations, potential markets for PV-10 is getting smaller

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next